How to Order

To place an order, contact Customer Service:

Call Toll-Free:
800-299-3431 		  Fax to:
978-436-7501
Monday-Friday    7:30 a.m. to 8:00 p.m. ET
Alternatively, log on to https://ecommerce.lantheus.com to place an online order


DEFINITY® Pricing Letter 10/1/2009
DEFINITY® Return Policy

Ordering Information:

Catalog Numbers:
DE4   4-Vial Kit US DEFINITY®
VMIX   VIALMIX®*
IPIN   Box of 4 Intellipins®

Shipping Information:

Freight free with 2 business day delivery. Product ships ambient and requires
refrigeration upon delivery. Overnight delivery is available for a $25.00 charge.

*A VIALMIX® is provided at no charge to customers who use DEFINITY®.

INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

CONTRAINDICATIONS

Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING: Serious Cardiopulmonary Reactions 

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINDICATIONS).
  • In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after DEFINITY® administration (see WARNINGS).
  • Always have resuscitation equipment and trained personnel readily available.


In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please See Full Prescribing Information and Letter to Healthcare Providers.

HOME